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Objectives:The objective of this study was to identify the mechanisms of resistance to nifurtimox and fexinida-
zole in African trypanosomes.
Methods:Bloodstream-formTrypanosoma bruceiwere selected for resistance to nifurtimox and fexinidazole
by stepwise exposure to increasing drug concentrations. Clones were subjected to WGS to identify putative resist-
ance genes. Transgenic parasites modulating expression of genes of interest were generated and drug suscep-
tibility phenotypes determined.
Results:Nifurtimox-resistant (NfxR) and fexinidazole-resistant (FxR) parasites shared reciprocal cross-resistance
suggestive of a common mechanism of action. Previously, a type I nitroreductase (NTR) has been implicated in
nitro drug activation. WGS of resistant clones revealed that NfxR parasites had lost.100 kb from one copy of
chromosome 7, rendering them hemizygous forNTRas wel as over 30 other genes. FxR parasites retained
both copies ofNTR, but lost.70 kb downstream of oneNTRalele, decreasingNTRtranscription by half. A single
knockout line ofNTRdisplayed 1.6- and 1.9-fold resistance to nifurtimox and fexinidazole, respectively. Since NfxR
and FxR parasites are 6- and 20-fold resistant to nifurtimox and fexinidazole, respectively, additional factors
must be involved. Overexpression and knockout studies ruled out a role for a putative oxidoreductase
(Tb927.7.7410) and a hypothetical gene (Tb927.1.1050), previously identified in a genome-scale RNAi screen.
Conclusions:NTR was confirmed as a key resistance determinant, either by loss of one gene copy or loss of gene
expression. Further work is required to identify which of the many dozens of SNPs identified in the drug-resistant
cel lines contribute to the overal resistance phenotype.
Introduction
There is an urgent need for new, safer and efective treatments for
the diseases caused by the protozoan parasitesTrypanosoma bru-
cei,Trypanosoma cruziandLeishmaniaspp. In the search for more
efective drugs for these ‘neglected diseases’, researchers have
chosen to reassess the therapeutic value of nitroaromatic com-
pounds, previously avoided in drug discovery programmes due
to perceived toxicity issues. This renewed interest largely stems
from the success of nifurtimox/eflornithine combination therapy
(NECT) for the treatment of the Gambian form of human African
trypanosomiasis (HAT). Treatment with NECT, consisting of oral
nifurtimox, a nitrofuran drug also used against Chagas’ disease,
combined with eflornithine infusions, has resulted in cure rates
of 97% leading to its inclusion on the WHO Essential
Medicines List.1Since its introduction in 2009, NECT has rapidly
become the treatment of choice for late-stageT. brucei gam-
bienseHAT and is now being used to treat.60% of cases (http:/
www.doctorswithoutborders.org). In the wake of NECT, the Drugs
for Neglected Diseases Initiative (DNDi) initiated a screen of
previously abandoned nitroheterocyclics and rediscovered the
2-substituted 5-nitroimidazole fexinidazole from Hoechst (Hoe
239), first shown to have antitrypanosomal activity almost
30 years ago.2In 2009, fexinidazole entered Phase I clinical trials
and is currently undergoing Phase II/III assessment. As the first
new clinical drug candidate for.30 years, there are now high
hopes that this nitroimidazole can become the first oraly avail-
able drug for both the haemolymphatic and meningoencephalitic
stages of HAT. In addition, the DNDi is now undertaking a Phase II
proof-of-concept study to evaluate fexinidazole for the treatment
of primary visceral leishmaniasis in Sudan (www.dndi.org).3Such
is the reversal in their fortunes; there are now several nitro drugs,
#The Author 2015. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http:/creativecommons.org/licenses/by/
4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
J Antimicrob Chemother
doi:10.1093/jac/dkv376
1of10
 Journal of Antimicrobial Chemotherapy Advance Access published November 17, 2015
 at University of Dundee on November 20, 2015
http://jac.oxfordjournals.org/
Downloaded from 
at various stages of development, populating the drug discovery
pipelines of al three trypanosomatid diseases (www.dndi.org).3,4
Given the prominence of nitro drugs curently in clinical devel-
opment, concerted eforts are now being made to elucidate their
mechanisms of action and potential mechanisms of drug resist-
ance. In African and South American trypanosomes, the mode
of action of nifurtimox involves reductive activation via an
NADH-dependent bacterial-like nitroreductase (NTR)5–7with the
formation of a cytotoxic, unsaturated open-chain nitrile deriva-
tive.5Resistance to nifurtimox in laboratory-generated clones of
T. cruziis associated with loss ofNTR.8Moreover, nifurtimox-
resistant (NfxR)T. bruceiare cross-resistant to fexinidazolein
vitroandin vivo.9Colectively, these studies are suggestive of a
common mechanism of action for these two nitroaromatic com-
pounds with NTR pivotal to their bioactivation. This hypothesis was
further substantiated in studies withLeishmania donovaniwhere
overexpression of a leishmanial homologue of NTR increased sus-
ceptibility to fexinidazole by 15-fold and nifurtimox by 19-fold.3
Reliance on a single enzyme, such as NTR, for drug activation
has the potential to leave nitroaromatics vulnerable to the emer-
gence of drug resistance. However, NTR activity has proven to be
an absolute requirement for virulence in the trypanosoma-
tids.8,10,11In recent studies withT. cruzi, laboratory-generated
benznidazole-resistant parasites were found to have lost a single
copy of the NTR gene, with mutations arising in the remaining
copy of the gene that abolished enzyme activity.10The virulence
of these ‘functional nul’ parasites was so reduced that the cap-
acity for such highly drug-resistantT. cruziparasites to spread
within the population would be severely compromised. Thus,
the requirement to retain NTR activity may limit the maximum
levels of nitro drug resistance achievable with NTR-activated
drugs such as nifurtimox, benznidazole and fexinidazole. The
potential for NTR-unrelated mechanisms of resistance to these
drugs has rarely been considered. In order to investigate this pos-
sibility, here we use genome-wide sequencing to study the resist-
ance mechanisms at play in bloodstream trypanosomes resistant
to fexinidazole and nifurtimox.
Materials and methods
Cel lines and culture conditions
T. bruceibloodstream-form ‘single marker’ S427 (T7RPOL TETR NEO)
and drug-resistant cel lines were cultured at 378C in HMI9-T medium12
supplemented with 2.5mg/mL G418 to maintain expression of T7 RNA
polymerase and the tetracycline repressor protein. Cultures were initiated
with 1×105cels/mL and subcultured when cel densities approached
1–2×106cels/mL.
In order to examine the efects of inhibitors on the growth of these
parasites, triplicate cultures containing the inhibitor were seeded at
1×105trypanosomes/mL. Cel densities were determined after culture for
72 h as previously described.13EC50values were determined using the
folowing two-parameter equation by non-linear regression using GraFit:
y= 1001+([I]/EC50)m (1)
where the experimental data were corrected for background cel density
and expressed as a percentage of the uninhibited control cel density. In
equation (1), [I] represents the inhibitor concentration andmis the slope
factor.
Drugs
Nifurtimox used in this study was a kind gift provided by Bayer, Argentina.
Fexinidazole was synthesized in-house as previously described.9
Generation of drug-resistant parasites
An NfxR line was generated by subculturing WTT. bruceiin the continuous
presence of nifurtimox.9Starting at a sublethal concentration of 1.5mM,
the drug concentration in the culture media was increased in a stepwise
manner, usualy by 2-fold. After a total of 140 days in culture, when trypa-
nosomes were able to survive and grow in 50mM nifurtimox, the resulting
T. bruceiline (designated NfxR) was cloned by limiting dilution in the
absence of nifurtimox. Three clones (NfxR1, NfxR2 and NfxR3) displaying
the highest resistance to nifurtimox were selected for further studies.
Resistance to fexinidazole was generated inT. bruceiin a similar manner,
starting at 1.0mM fexinidazole. Fexinidazole-resistant (FxR) clones were
derived from the resulting FxR line after 137 days in culture and clones
FxR1, FxR2 and FxR3 were selected for further analysis.
Generation of knockout and overexpression constructs
The primers used are summarized in Table S1 (available as Supplementary
data atJACOnline) and were designed using theT. brucei NTRsequence
in TriTrypDB (Tb427.07.7230) as a template. The accuracy of al assembled
constructs was verified by sequencing.NTRgene replacement cassettes
were generated by amplifying a region of DNA encompassing the 5′UTR,
ORF and 3′UTR ofT. bruceiNTR from genomic DNA with primers
5′UTR-NotI_F and 3′UTR-NotI_R, usingPfupolymerase. An endogenous
NotI site present within the 3′UTR was silenced using primers 3′UTR_
mut_G89C_F and 3′UTR_mut_G89C_R and the QuikChange Lightning
Site-Directed Mutagenesis Kit (Stratagene) as per the manufacturer’s
guidelines. This mutated sequence was then used as a template for the
amplification of the individual regions used in the assembly of replace-
ment cassettes containing the selectable drug resistance genes puro-
mycinN-acetyl transferase (PAC) and hygromycin phosphotransferase
(HYG) as previously described.14The gene replacement construct (PAC)
of theT. bruceigene Tb927.1.1050 was generated in an identical manner.
The gene replacement construct (HYG) of theT. bruceigene Tb927.7.7410,
encompassing the 450 bp upstream and downstream of the ORF, was
commercialy synthesized (GeneArt, Invitrogen).
To generate an overexpression construct of theT. bruceihypothetical
gene annotated Tb927.7.7410, the ORF was amplified from genomic
DNA using sense and antisense primers and cloned into pCR-Blunt
II-TOPO (Invitrogen). The pCR-Blunt II-TOPO-Tb927.7.7410 construct
was then digested with HindIII and PacI and the resulting fragment
ligated into the HindIII/PacI cloning site of a modified pLew82
tetracycline-inducible expression vector,14,15resulting in the introduction
of a C-terminal triple haemagglutinin (HA) epitope tag into the expressed
protein. Similarly, theNTRgene and a mutated version of theNTRgene,
encoding a mutation of residue 106 from Val to Ile, was generated
by site-directed mutagenesis with the NTRMUTprimers (Table S1) as
described above. The mutated gene was then ligated into the HindIII/
PacI cloning site of the original pLew82 tetracycline-inducible expression
vector.15
Generation of transgenic cel lines
Mid-log bloodstream trypanosomes were transfected with either knockout
or recovery constructs using the Human T-Cel Nucleofector kit and
nucleofector (Amaxa, program X-001). Folowing transfection, cels were
alowed to grow for 16 –24 h prior to appropriate drug selection (hygromy-
cin and puromycin at 4 and 0.1mg/mL, respectively). Cloned cel lines were
generated by limiting dilution, maintained in selective medium and
removed from drug selection for one passage prior to experiments.
Wylieet al.
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Verification of single gene knockouts (SKO) by PCR
PCR primer pairs 5′UTR_2595_F and 3′UTR_+600_R (outer primers) and
5′UTR_2107_F and 3′UTR_+152_R (inner primers) (Table S1) were used
to verify the removal of a single alelic copy ofNTRfrom bloodstream
parasites. Genomic DNA from putative NTRSKOcel lines was prepared
and PCR was carried out usingPfupolymerase. Similar confirmatory
studies were carried out with primer pairs 5′UTR_+500 and HYG R for
Tb927.7.7410SKOcel lines (Table S1).
Southern blot analyses of transgenic T. brucei cel lines
The 5′UTR ofT. bruceiTb927.1.1050 was amplified by PCR [using the pri-
mers previously described for the cloning of the single knockout (SKO) con-
struct] and the PCR DIG Probe Synthesis Kit (Roche). The resulting
DIG-labeled product was used as a probe. Samples of genomic DNA
(5mg) from WT and transgenic cel lines were digested with appropriate
restriction endonucleases; then, the digestion products were separated
on a 0.8% agarose gel and transferred onto a positively charged nylon
membrane (Roche). The membrane was hybridized overnight in DIG
Easy Hyb solution (Roche) at 428C with the DIG-labeled 5′UTR probe
(2mL of PCR product). Folowing hybridization, membranes were washed
twice in low-stringency conditions (258C, 5 min, 1×SSC with 0.1% SDS)
and twice in high-stringency conditions (688C, 15 min, 0.5×SSC with
0.1% SDS), where 1×SSC comprises 150 mM sodium chloride and
50 mM sodium citrate (pH 7.0). Bound probe was detected using the
DIG immunological detection kit (Roche) as per the manufacturer’s
instructions.
Western blot analysis of T. brucei cel lysates
Overexpression of the protein encoded by the gene Tb927.7.7410 was
induced by the addition of tetracycline (2mg/mL) for 72 h prior to analysis
by western blotting.T. bruceiwhole-cel extracts (1×107parasites per
lane) were separated by SDS – PAGE and subsequently transferred onto
nitrocelulose. After blocking with 5% skimmed milk in PBS for 1 h, blots
were incubated with anti-HA mouse monoclonal antibody (Roche,
1 : 500), washed in PBS containing 0.1% (v/v) Tween 20 and then incubated
with a secondary antibody (horseradish peroxidase-conjugated anti-
mouse IgG, R&D Systems, Minneapolis, MN, USA; 1 :5000 dilution).
Immunoblots were developed using the ECL Plus (enhanced chemilumin-
escence) system from GE Healthcare (Piscataway, NJ, USA).
Quantitative PCR (qPCR)
Levels ofNTRtranscript in resistant and WT parasites were analysed by
qPCR using telomerase reverse transcriptase (TERT, Tb11.01.1950) as a ref-
erence gene. RNA was prepared from 1×107parasites using the RNeasy
Kit (Qiagen) as per the manufacturer’s instructions. cDNA was then gener-
ated from these samples using the iScript cDNA Synthesis Kit (Bio-Rad). Al
qPCR reactions were performed with PerfeCTa SYBR Green FastMix for iQ
usingtheprimersetsdescribedinTableS1andaBio-RadCFX96
Real-Time PCR Detection System. Al statistical analyses are unpaired, two-
tailedt-tests with a 95% CI and were performed using GraphPad Prism
software.
WGS and genomic variant analysis
Genomic DNA was prepared fromT. bruceiclones NR-B_427 (NfxR1),
NR-D_427 (NfxR2), NR-G_427 (NfxR3), FR-A_427 (FxR1), FR-C_427 (FxR2)
and FR-E_427 (FxR3). For each sample, 5mgofgenomicDNAwasused
to produce amplification-free Ilumina libraries with fragment sizes of
350–450 bp.16Sequencing was carried outonanIluminaHiSeq2000
sequencer according to the manufacturer’s standard sequencing protocol
and yielded 33.6 – 43.8 milion reads of 100 bp length per library for the
drug-resistant lines. To alow direct comparison of genetic variant cals
from these data with variant cals from shorter reads of an Ilumina
sequencing run of theT. bruceireference strain Lister 427 (lane 5189_8,
67.8 milion reads of 76 bp length), the 100 bp reads were hard clipped
to a length of 76 bp. The resulting datasets represented a nominal sequen-
cing coverage of the 35 MbT. bruceigenome of 73- to 95-fold
(drug-resistant strains) and 147.2-fold (Lister 427). The Ilumina data
were aligned against theT. b. bruceiTREU927 reference genome assem-
bly17using SMALT v0.7.4 (http:/www.sanger.ac.uk/resources/software/
smalt/). For variant caling, the alignment was run employing an exhaust-
ive search (2x) and with parameters wordlen¼13 (2k), skipstep¼1(2s),
minscor¼0.65 (2m) and insertmax¼1000 (2i). To assess relative read
coverage and copy number variations, the alignment runs were repeated
using the same parameters but additionaly with repetitive mapping (2r)
enabled. Variants were caled using SAMtools v0.1.19 mpileup (2Q 15 for
baseQ/BAQ filtering) and BCFtools.18To exclude the hypervariable subtelo-
meric regions, only variants found in the folowing chromosomal core
regions were included in the downstream analyses: Tb927_01_v4:
202695– 988120; Tb927_02_v4: 259723 – 1161408; Tb927_03_v4:
146614– 1602 829; Tb927_04_v4: 80 380– 1467268; Tb927_05_v4:
72088– 1366595; Tb927_06_v4: 111 409– 1414033; Tb927_07_v4:
26571– 2177541; Tb927_08_v4: 135 192– 2476033; Tb927_09_v4:
325850– 2394 987; Tb927_10_v5: 55 698– 3993 940; and Tb927_
11_01_v4: 36585 –4 482610. SNP cals were further filtered for al of the
folowing: for a minimum of eight ‘high-quality’ base cals (‘DP4’); for a
minimum phred-scale QUAL score of 20; for a maximum phred-scale like-
lihood of the best genotype cal of 5 (‘PL1’); for a minimum phred-scale
likelihood of the second best genotype cal of 10 (‘PL2’); for a minimum
strand biasPvalue of 0.01 (first of ‘PV4’); for a maximum ratio of conflict-
ing base cals for homozygous genotypes of 5% and, for positions with a
minimum and maximum read depth of three times the median read depth
observed for that chromosome: for a minimum mapping quality of 20 and
for a minimum distance of 10 nucleotides from the nearest INDEL cal.
Files in Variant Cal Format (VCF) listing al 190 064 genomic positions at
which any one of the six drug-resistant and the parental parasite lines
had a variant cal are available at http:/dx.doi.org/10.15132/10000107.
The raw sequence data are available under the folowing accession num-
bers at the European Nucleotide Archive (http:/www.ebi.ac.uk/ena):
Tb427 WT (SM_S427): ERS012470; NR-B_427: ERS017528; NR-D_427:
ERS017529; NR-G_427: ERS017530; FR-A_427: ERS017531; FR-C_427:
ERS017532; and FR-E_427: ERS017533.
Results
NfxR and FxR trypanosomes
In our previous studies we investigated the ease with which resist-
ance to nifurtimox and fexinidazole could be generatedin vitroin
T. brucei(S427) bloodstream trypanosomes.9In our current study,
resistance was readily achievable with the resulting NfxR (NfxR1 –
2) and FxR (FxR1 – 2) clones being 6- and 11-fold resistant to
nifurtimox and fexinidazole, respectively, compared with WT
(Table1). NfxR trypanosomes demonstrated cross-resistancein
vitroandin vivoto fexinidazole, with FxR parasites similarly cross-
resistant (Table1). The EC50values determined for these cel lines
in our current study are in good agreement with previously pub-
lished data.9However, in this study, the Hil slope values for the
FxR cel lines (1.2 – 1.5) are half as steep in comparison with the
WT parasite (2.6) and its geneticaly manipulated derivatives.
This feature was not evident in our previous study (e.g. Hil slopes
of 1.6 versus 1.4 for WT and FxR parasites, respectively) and is
unique to FxR parasites. The significance of this observation is
not clear, but may suggest some diferences in the mechanisms
of action of fexinidazole and nifurtimox. The reciprocal cross-
resistance relationship observed here with NfxR and FxR parasites
Nitro drug resistance in trypanosomes
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strongly supports our hypothesis that a predominantly similar
mechanism of action is involved for these two compounds.9
However, it is notable that the level of resistance to fexinidazole
in the selected lines is always greater than the resistance to nifur-
timox, regardless of which drug was used in the selection. Here,
the resistance mechanisms exploited by both resistant lines are
studied.
Role of NTR in NfxR and FxR drug resistance
Bioactivation of nifurtimox and fexinidazole is catalysed by type I
NTR enzymes in bothT. bruceiandLeishmania.3,7The potential
role of this enzyme in the nitro drug resistance mechanisms of
NfxR and FxR trypanosomes was investigated. To determine
whether any mutations within theNTRgenes of these cel lines
could account for nitro drug resistance, the ORF of TbNTR, flanked
by 100 bp at the 5′-terminus and 150 bp at the 3′-terminus, was
amplified by PCR from the genomic DNA of each cel line and ana-
lysed by in-house sequencing in Dundee. TheNTRgene in al NfxR
clones was found to contain a point mutation that encoded a sin-
gle amino acid change (V106I). This mutation was not present in
any of the FxR clones. To assess the potential impact of this amino
acid change on the activity of NTR, a tetracycline-inducible
ectopic copy of the mutant gene was introduced into WT cels.
Al tetracycline-induced clones, derived from the resulting
TbNTRV106I-overexpressingT. bruceicel line, were found to be
9-fold more susceptible to nifurtimox than the parental WT
cels with a mean EC50value 0.38+0.01mM(Table1). This is very
similar to the 10.6-fold increase in susceptibility seen with cels
overexpressing WT NTR (EC50value 0.32+0.01mM). Colectively,
these data indicate that mutant TbNTRV106Iis capable of activating
nifurtimox in bloodstream trypanosomes and that this mutation is
unlikely to play any significant role in nitro drug resistance.
An initial Southern analysis of genomic DNA from the nitro
drug-resistant trypanosomes appeared to suggest that a single
alele ofNTRhasbeenlostinbothNfxR1andNfxR2cellines.
However, FxR clones appeared to maintain bothNTRaleles
(Figure S1). The impact of a reduction in theNTRcopy number
on nitro drug susceptibility was investigated by generatingNTR
SKO cel lines. A single copy of theNTRgene was replaced with
either the hygromycin resistance gene (HYG) or the puromycin
resistance gene (PAC) by homologous recombination and drug
selection. The successful removal of single copies of theNTR
gene from these diploid parasites was confirmed by PCR
Table 1.Susceptibility of WT, nitro drug-resistant and transgenicT. bruceicel lines to nifurtimox and fexinidazole
Cel line Nifurtimox, EC50,mMa Resistance factor Fexinidazole, EC50,mMa Resistance factor
WT 3.4+0.09 (2.7) 1 1.4+0.13 (2.6) 1
NfxR
clone 1 19.7+1.4 (2.1)b 5.8 14.5+1.5 (1.2)b 10.4
clone 2 22.3+1.6 (2.2)b 6.5 16.8+2.4 (1.4)b 12
FxR
clone 1 19.1+1.0 (2.4)b 5.6 13.2+1.0 (1.5)b 9.4
clone 2 18.3+0.9 (3.4)b 5.4 13.0+1.1 (1.2)b 9.3
NTRSKO
HYG 5.8+0.1 (2.3)b 1.7 2.6+0.2 (2.2)c 1.9
PAC 6.5+0.1 (1.9)b 1.9 2.8+0.1 (2.1)c 2.0
Tb927.1.1050SKO
clone 1 2.2+1.0 (2.2)d 1.0 1.9+0.7 (2.8) 1.4
NTRSKO/Tb927.1.1050SKO
clone 1 3.8+0.2 (2.4)d 1.8 2.8+0.2 (2.5) 2.0
clone 2 4.0+0.3 (2.0)d 1.7 2.7+0.4 (2.5) 1.9
Tb927.7.7410OE
clone 1 3.1+0.2 (3.4) 0.9 1.2+0.05 (2.7) 0.9
clone 2 3.1+0.2 (2.3) 0.9 1.3+0.06 (2.1) 0.9
TbNTRV106IOE
clone 1 0.38+0.01 (2.1)b 0.11 NDe —
TbNTROE
clone 1 0.32+0.01 (2.0)b 0.09 NDe —
aResults are the mean and standard error of at least three independent experiments. Slope factors are indicated in brackets.
bUnpairedt-test determined these EC50values to be significantly diferent from WT values with a statistical significance ofP,0.0001.cUnpairedt-test determined EC50values to be significantly diferent from WT values with a statistical significance ofP≤0.001.dThe EC50value for nifurtimox against WT parasites in this dataset was 2.3+0.3mM with the resistance factors calculated accordingly.eNot determined.
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(Figure1). The resulting SKOHYGand SKOPACcel lines showed no
major growth phenotype with doubling times of 8 h, similar to
the 7.3 h doubling time of WT parasites. However, SKOHYGpara-
sites were found to be 1.7- and 1.9-fold less susceptible than
WT T. bruceito nifurtimox and fexinidazole, respectively
(Table1). Similarly, SKOPACcels were 1.9-fold less susceptible to
nifurtimox. Given that NfxR cels demonstrate a 6-fold shift in
their susceptibility to nifurtimox, it is clear from these data that
the loss of a single alele ofNTRmay not be entirely responsible
for the levels of nitro drug resistance seen with these cels and
additional factors may be involved.
WGS of NfxR and FxR cel lines reveals large-scale losses
of single aleles and numerous genetic variants
In an attempt to identify any additional factors that may be
involved in the drug resistance phenotypes of NfxR and FxR cel
lines, the genomes of each clone were sequenced. The sequence
data readily confirmed the loss of one copy of the NTR locus for
the NfxR parasites, rendering a region of.100 kb hemizygous
(Figure2a). This includes 32 putative genes, including a putative
oxidoreductase (Tb927.7.7410) (Table S2). For the FxR parasites,
the 3′-end of the chromosomal core region of chromosome
7 was likewise found to be present in only a single copy, but
here the hemizygous region started 20 kb downstream of the
NTR locus (Figure2a) with hemizygosity for 22 genes (Table S2).
In addition, the sequencing data revealed another 5.8 kb region
on chromosome 1, encompassing Tb927.1.1050, that has been
lost solely in the NfxR cel lines (Figure2b). Comparing the geno-
type cals of the drug-resistant lines with those of the parental
strain also uncovered many dozens of SNPs that are predicted
to result in non-synonymous amino acid changes that could
potentialy contribute to the observed drug resistance phenotypes
(Table S3). Unfortunately, because of the repetitive nature of the
T. bruceigenome, which contains many duplicated genes, such
lists of genomic variant candidates are often too long to be experi-
mentaly verified one by one. Below, we report the experimental
folow-up of the most prominent genetic variants.
Does the putative oxidoreductase (Tb927.7.7410) play a
role in nitro drug resistance?
Loss of genetic material from a single copy of chromosome 7 in
NfxR and FxR parasites resulted in the deletion of a putative oxi-
doreductase. Since this class of enzymes has the potential to
catalyse the reduction of nitro drugs, the enzyme’s role in the acti-
vation of fexinidazole and nifurtimox was investigated. A triple HA
epitope-tagged version of the putative oxidoreductase, encoded
by gene Tb927.7.7410, was overexpressed in bloodstream trypa-
nosomes. Expression of the putative oxidoreductase in these
transgenic parasites was confirmed by western blotting using
an anti-HA mouse monoclonal antibody (Figure3a). An extra
band at 42 kDa is visible in the overexpressing lines consistent
with the predicted molecular mass of the tagged protein. Two clo-
nal cel lines expressing the tagged oxidoreductase were then
assessed for their susceptibilities to both nifurtimox and fexinida-
zole; these clones were found to be equaly susceptible to the
nitroaromatic compounds as WT parasites (Table1). A proteomic
study of the mitochondria of procyclicT. brucei19established that
this oxidoreductase may be associated with subcomplex Iaof the
respiratorychain.However,preliminaryimmunofluorescence
studies suggested that the HA-tagged enzyme was predomin-
ately localized to the cytosol of bloodstream trypanosomes.
Since we cannot confirm whether or not our overexpressed,
tagged oxidoreductase is correctly localized in the cel, or indeed
functional, additional studieswere carried out. A single copy
of Tb927.7.7410 was replaced in WT trypanosomes (Tb927.
7.7410SKO)andalsoinNTRSKO(NTR/Tb927.7.7410SKO) parasites,
thus mimicking the genetic composition of NfxR and FxR parasites
(Figure3b and c). Removal of a single copy of this gene was found
to have no impact on the nitro drug susceptibility of either WT
parasites or in cels lacking a single copy ofNTR(Figure3d).
Colectively, these data do not support a role for this putative
oxidoreductase in the mechanism of action of, or resistance to,
fexinidazole and nifurtimox inT. brucei.
Hypothetical protein Tb927.1.1050
Genome-wide sequencing also revealed that one alelic copy of
the gene Tb927.1.1050, which encodes a putative metalo-
dependent phosphatase, was lost from the NfxR cloned cel
lines. Changes to this uncharacterized gene drew our attention
since it had previously been identified in genome-scale RNA inter-
ference target sequencing (RIT-seq) screens of nifurtimox in
T. brucei.20To investigate any potential role in nifurtimox resist-
ance, a single copy of Tb927.1.1050 was replaced in WT trypano-
somes (Tb927.1.1050SKO) and also inNTRSKOparasites (Figure4).
3¢ UTR5¢ UTR NTR
PAC
3¢ UTR5¢ UTR NTR
HYG
(b)
(a)
Outer primers Inner primers
3
2
1.65
10.85
0.65
WT HYG PAC WT HYG PACkb
Figure 1.Generation and analysis ofNTRsingle gene knockout cel lines.
(a) A schematic representation ofNTRgene deletion in the knockoutT.
bruceicel lines SKOHYG(top) and SKOPAC(bottom). Arrows indicate the
position of PCR primer pairs 5′UTR_2595_F and 3′UTR_+600_R (outer
pair) and 5′UTR_2107_F and 3′UTR_+152_R (inner pair). (b) Agarose gel
electrophoresis of PCR products generated with the primer pairs
indicated in (a). The template genomic DNA was derived from WTT.
brucei,SKOHYGclone 1 and SKOPACclone 1.
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Figure 2.Hemizygous regions in the drug-resistant parasite lines identified by WGS. The read coverage plots show the relative read depth (analysed in
windows of 800 bp width) by plotting the log2-based ratio of the read depth observed in a given window over the average read depth of the
corresponding chromosome. A log2-based relative read depth of21 therefore indicates a read coverage that is 0.5-fold that of the average read
depth, which may be due to the loss of one of the two aleles in that region (hemizygosity). Note the variable but highly reproducible (across the
different parasite lines) nature of the read coverage, which is caused by differences in sequence read mapping efficiency across the genome
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Removal of a single copy of this gene was found to have abso-
lutely no impact on the nitro drug susceptibility of either WT para-
sites or in cels lacking a single copy ofNTR(Table1). It is
perplexing that this gene has been implicated in nitro drug resist-
ance in both RIT-seq and WGS studies; however, our data do not
support a role for this putative metalo-dependent phosphatase
in the mechanism of action of, or resistance to, nifurtimox in
T. brucei.
NTR transcript levels in NfxR and FxR cel lines
Confirming our preliminary Southern analysis (Figure S1), genome-
wide sequencing revealed that both NfxR clones had lost a single
copy ofNTRwhile FxR clones maintained both copies. However, a
large section of chromosome 7 downstream ofNTRappeared to
have been deleted from single aleles of both the NfxR and FxR
cel lines. This includes a divergent strand-switch region, i.e. a prob-
able transcription start site for RNA polymerase II,21between
Tb927.7.7480 (a putativetrans-sialidase) and Tb927.7.7490
(a conserved hypothetical protein). The impact of this deletion on
the transcript levels ofNTRwas determined by qRT-PCR. Relative
levels ofNTRcDNA in WT, NfxR1 and FxR1 cel lines were normalized
using the reference housekeeping gene telomerase reverse tran-
scriptase (TERT).NTRtranscript levels in NfxR1 and FxR1 clones
were reduced to 0.42+0.06 and 0.6+0.07 of the levels seen in
the WT parasites, respectively. The 50% reduction in the levels
ofNTRmRNA is consistent with the loss of a single alele ofNTR
from NfxR cels, already demonstrated by genome sequencing.
Further, it suggests that the loss of genetic material downstream
ofNTRleaves FxR cels unable to transcribe one alele ofNTRand
that these cels are functionaly hemizygous for NTR despite main-
taining both alelic copies of this gene.
Discussion
The pivotal role of type I NTR enzymes in the activation of nifurti-
mox, benznidazole and fexinidazole in trypanosomatids is wel
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Figure 3.Overexpression and single gene knockout of a putative oxidoreductase encoded by Tb927.7.7410 in bloodstream trypanosomes. (a) Overexpression
of the HA-tagged protein encoded by Tb927.7.7410 was induced by the addition of tetracycline 72 h prior to analysis. Cel lysates (1×107parasites in each
lane) were separated by SDS –PAGE and analysed by western blotting with a rabbit anti-HA antibody. Lysates were derived from WT cels (lane 1) and cels
transfected with pLEW82-7410-HA3(clone 1 in lane 2 and clone 2 in lane 3). Arows indicate the position of Tb927.7.7410. (b) Schematic representation of the
ORF of Tb927.7.7410 flanked by 5′UTR and 3′UTR regions. Successfuly replacing a single copy of this gene withHYGalows a PCR fragment of 1.5 kb to be
generated by specific primers designed to the 5′UTR (outside of the gene replacement construct) andHYG. (c) Agarose gel electrophoresis of PCR products
generated with the primer pairs indicated in (b). The template genomic DNA was derived from WTT. brucei(lane 1), Tb927.7.7410SKOclone 1 (lane 2) andNTR/
Tb927.7.7410SKO(lane 3). (d) EC50values of 1.6+0.03, 1.5+0.03, 3.4+0.06 and 3.1+0.04mM were determined for nifurtimox against WT (open circles),
Tb927.7.7410SKO(filed circles),NTRSKO(open squares) and Tb927.7.7410/NTRSKO(filed squares) trypanosomes, respectively.
especialy in regions of repetitive sequence. The location of genes along the chromosomes is indicated below the graphs. (a) The plot shows the 3′-end
(the ‘right-hand side’) of the chromosome core region of chromosome 7. A 50% reduction in read depth is apparent for the three replicate NfxR lines for
more than 100 kb starting from around genomic position 2065600 and similarly for the three replicate FxR lines starting from around genomic position
2 104 500. The genomic variants listed in Table S3 confirm the expected concomitant loss of heterozygosity in this region. The hemizygous region
observed in the NfxR lines includes NTR, whereas the hemizygous region in the FxR lines does not, although it stil apparently overlaps the
polycistronic transcription unit in this region. (b) A 5.8 kb hemizygous region on chromosome 1 observed only in the three replicate NfxR lines.
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established.3,7,8Therefore, it is no surprise that in our current
study we confirm that reduced levels ofNTRexpression are prin-
cipaly responsible for resistance in our NfxR and FxR cel lines.
Generation of resistance to nifurtimox in bloodstream trypano-
somes resulted in the loss of over 100 kb from one alele of
chromosome 7. This deletion rendered NfxR parasites hemizygous
forNTRas wel as over 30 other genes. FxR parasites retained both
copies ofNTR, but it appears that a deletion 20 kb downstream
left these parasites unable to transcribe one alele of this gene.
To our knowledge, this mechanism has not been observed previ-
ously in trypanosomes and underlines the importance of not only
determining gene copy number, but also possible changes in the
relevant transcription unit. Significant chromosomal deletions of
this nature are a common phenomenon in trypanosomes,10,22,23
which are renowned for their genome plasticity.24
To quantify the impact of the loss of oneNTRcopy, an SKO cel
line was generated.NTRSKOtrypanosomes demonstrated 1.6- and
1.9-fold resistance to nifurtimox and fexinidazole, respectively,
compared with the parental WT line. Bearing in mind the levels
of nitro drug resistance seen with our NfxR and FxR cel lines,
these findings clearly indicate that other mechanisms, in addition
to loss of expression ofNTR, must contribute to resistance.
Detection of a mutation within the remaining copy ofNTRin
NfxR parasites (NTRV106I) was eliminated as a resistance factor,
because the resulting mutant protein retained its NTR activity.
In our hands, it has proved impossible to obtain pure recombinant
T. bruceiNTR,25unlike other reports onT. cruziNTR,8,10making it
impossible to carry out more detailed enzymatic studies.
In addition, we were able to efectively rule out a putative oxi-
doreductase, lost in the deletion of chromosome 7, as playing any
role in resistance. In ruling out these factors, we must consider
that 1 of the 44 SNPs common to both drug-resistant cel lines
may be contributing to the drug resistance phenotype (Figure5
and Table S4). The mechanisms that may lead to drug resistance
in trypanosomatids can be generaly classified into three categor-
ies: mechanisms that lower the drug levels within the cel;
mechanisms that afect the main enzymes interacting with the
drug (in the case of pro-drugs these can include the main activat-
ing proteins); and general defence and repair mechanisms.26With
this in mind, it is entirely plausible that a mutation within a specific
target may reduce its affinity for the cytotoxic open-chain nitrile
metabolite generated folowing bioreduction of nifurtimox.7
Alternatively, SNPs within transporters could reduce the uptake
or increase the efflux of both nifurtimox and fexinidazole. A non-
synonymous SNP was observed in a putative membrane trans-
porter (Tb9.211.2900) in both NfxR and FxR clones (Table S4).
Unfortunately, due to the sheer number of SNPs identified in the
genomes of FxR and NfxR parasites, we are unable to systematic-
aly assess their roles in drug resistance.
The mechanisms underlying resistance to nifurtimox inT. brucei
have also recently been assessed using a genome-scale RIT-seq
screen.20In this elegant study, a total of 75 genes were identified
as being associated with nifurtimox resistance, with 8 genes found
to have a strong association. Of these eight genes, six were found
to directly or indirectly reaffirm the dominant role of the NTR in
activation of nifurtimox. The major primary signature in the nifur-
timox RIT-seq profile identifiedNTR. In addition, a putative flavoki-
nase, believed to be involved in the conversion of riboflavin to FMN,
the essential cofactor of NTR, was also identified. The remaining
four signatures were assigned to genes involved in ubiquinone
biosynthesis, supporting the hypothesis that NTR functions as
an NADH dehydrogenase transferring electrons from NADH to
ubiquinone generating ubiquinol.8Adirectcomparisonofthe
‘hits’ from RIT-seq screening of nifurtimox and the SNPs identified
in the genome sequence from NfxR and FxR cel lines confirmed
thatNTRwas common to both the RIT-seq and NfxR datasets
(Figure5and Table S4). In addition, a hypothetical gene
(Tb927.1.1050), identified as a copy number variant in our NfxR
dataset, was also identified via RIT-seq; however, our subsequent
analysis could not demonstrate a role in nitro drug resistance.
Colectively, these and other data continue to place trypanoso-
matid NTR enzymes firmly at the centre of the mechanisms of
action/resistance of both nifurtimox and fexinidazole. It is
4.5 kb
2 kb
2 kb
(a)
(b)
4.5 kb
2
HYG
1 3
Tb927.1.1050
Figure 4.Generation of a Tb927.1.1050 single gene knockout in NTR
SKOHYGcels. (a) The black bars represent the 5′UTR region upstream of
the ORF of Tb927.1.1050 used as a probe in Southern blot analysis. SalI
sites with expected fragment sizes are shown. The endogenous
Tb927.1.1050 gene contains a SalI site, which results in a 2 kb band.
Successful replacement of one alelic copy of the endogenous gene with
HYG, which does not contain a SalI site, results in a 4.5 kb fragment.
(b) Southern blot analysis of SalI-digested genomic DNA (5mg) from
T. brucei NTRSKOPACcels (lane 1),NTRSKOPACbackground and Tb927.
1.1050 SKOHYGclone 1 cels (lane 2) andNTRSKOPACbackground and
Tb927.1.1050 SKOHYGclone 2 cels (lane 3). The 5′UTR of the gene
Tb927.1.1050 was used as a probe. A faint non-specific band can be
seen at 3 kb in al three lanes.
25
7412 0
44 10
NfxR
(n = 70)
FxR
(n = 56)
Nfx RIT
screen
(n = 75)
Figure 5.Venn diagram of overlapping gene ‘hits’ from RIT-seq screening
of nifurtimox inT. bruceiand of genes with high-confidence SNPs from
WGS of NfxR and FxR trypanosomes. See Table S4 for further details.
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surprising that there is so little overlap between the results of
RIT-seq screening with nifurtimox and WGS of laboratory-
generated NfxR cel lines. It is clear that both approaches have
strengths and weaknesses. RNAi methodologies such as RIT-
seq are unable to detect mutations that retain biological function
whilst losing susceptibility to a specific inhibitor (e.g. SNPs in
Figure5). RIT-seq cannot detect gene amplifications or changes
in regulatory elements that lead to resistance. Resistance involv-
ing two or more genes acting in concert cannot be detected using
RIT-seq. The read density cut-off in RIT-seq ascribed as signifi-
cant is somewhat arbitrary (.100) and may be set too high
(e.g. Tb927.1.1050 is in the secondary read density category).20
Finaly, short-term knockdown of essential pathways such as
riboflavin or ubiquinone biosynthesis may have a long-term fit-
ness cost in the drug selection approach. Moreover, the time
taken to generate resistance to compounds in the laboratory
combined with the intrinsicaly high mutation rate of trypanoso-
matids can make the identification of resistance-relevant SNPs
extremely difficult. Indeed, the chemical stress that results
from prolonged drug exposure can itself lead to mutations unre-
lated to the general mechanism of drug resistance. These studies
ilustrate the value of pooling datasets from diferent approaches
in studies of drug resistance/mechanism of action.
ThelaunchofNECTin2009demonstratedthatnitrodrugs
could be used to treat trypanosomatid diseases safely and
effectively. As a result, there has been a marked increase in the
number of nitroaromatic compounds in development for these
diseases,27including for the first time a clinical candidate for vis-
ceral leishmaniasis.3With the likelihood that this class of com-
pounds wil be more extensively used in the clinic, it is
imperative that we understand not only the mechanisms of
action of these drugs but also the likely mechanisms of drug
resistance. In this and our previous studies, we have shown
that NfxRT. bruceiare cross-resistant to fexinidazole.9It is of par-
ticular concern that our NfxR parasites were in fact considerably
more resistant to fexinidazole than nifurtimox. Should this
observation be repeated in a clinical setting, widespread resist-
ance to nifurtimox as part of NECT could compromise the future
use of fexinidazole. In this case, cross-resistance is largely due to
their common NTR-mediated mode of action. This ilustrates the
risk of simultaneously developing multiple nitroaromatic drugs,
with potentialy similar mechanisms of action, for the treatment
of trypanosomatid diseases. In such a scenario, a single drug
resistance mechanism could result in multiple compound fail-
ures. Thus, as novel nitro drugs such as DNDI-VL-2098 are devel-
oped,4defining their mechanisms of action should be a matter of
urgency.
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